The European Commission and AstraZeneca said on Friday that they had reached a settlement with the British pharmaceutical company to provide the remaining doses of the Covid 19 vaccine and had ended the pending litigation in Brussels.
Tea Settlement Clears an important overhang for. AstraZeneca, Which is cheap and easy to transport. Vaccinated There have been several failures, including concerns about the lawsuit and possible side effects. It also allows United Europe Accelerate vaccinations during shortages.
Under the settlement, AstraZeneca has pledged to deliver 60 million doses of its vaccine by the end of the third quarter of this year, 75 million by the end of the fourth quarter and 65 million by the end of the first quarter of 2022.
Launched by the European Commission. Legal action Against AstraZeneca in April for not honoring the supply agreement. Covid-19 Due to the lack of a “reliable” plan to ensure vaccines and timely delivery.
“There is a significant difference in vaccination rates between our member countries, and the continued availability of vaccines, including AstraZeneca, is important,” said Stella Carrickides, EU Commissioner for Health and Food Safety.
We are pleased to find a mutually satisfactory solution that benefits citizens and citizens through our global COVAX commitment.
– Stella Caricides (KSKyriakidesEU) September 3, 2021.
The EU’s executive body said the new agreement would provide member states with a regular delivery schedule and a limited rebate if there were any delayed deliveries.
Brussels said the shipment would honor the pre-purchase agreement the EU signed with AstraZeneca a year ago. Millions of food have already been delivered to EU member states, but the 27-nation bloc has not lived up to expectations.
Rod Dober, executive vice president of biopharmaceuticals in Australasia, said: “I am delighted that we have reached a common understanding that allows us to move forward and work closely with the European Commission. Infectious diseases can be controlled. ”
The AstraZeneca vaccine is manufactured at the University of Oxford in the United Kingdom and is sold on a non-profit basis. This version is cheaper and easier to store than many competitors.
Officials have accused AstraZeneca of prioritizing UK vaccine deliveries at the behest of the European Union, and European Commission lawyers have gone to court to demand delivery or impose heavy fines daily for any ongoing reductions.
A Belgian court ruled in June that AstraZeneca had “seriously violated” its agreement with the European Union.
But the firm argued that its agreement with the block only required it to make “the best efforts” to meet its delivery target, and that production disruptions at its European plants were inevitable.
Disappointed by the slowdown in supply, the European Union has since made the workhorse of its procurement program another vaccine developed by the American giant Pfizer and Germany’s Biotech.
(France24 with AFP, AP and Reuters)